Clinical Study Results
The table below shows the most common adverse reactions that happened in 2 or
more participants during the study. There were other adverse reactions, but these
happened in fewer participants.
Most common adverse reactions during the study
AZD9496 Fulvestrant
(out of 22 participants) (out of 24 participants)
Nausea 18.2% (4) 4.2% (1)
Tiredness 9.1% (2) 4.2% (1)
Hot flush 0.0% (0) 12.5% (3)
Diarrhoea 4.5% (1) 4.2% (1)
Headache 4.5% (1) 4.2% (1)
How has this study helped patients and
researchers?
This study helped researchers learn more about how AZD9496 works in
participants with breast cancer compared to fulvestrant.
Researchers look at the results of many studies to decide which treatments work
best and are safest. This summary shows only the main results from this one study.
Other studies may provide new information or different results.
Further clinical studies with AZD9496 are not planned.
7